Indoco Remedies Ltd

Merger & Restructuring

Indoco Remedies Merger & Restructuring Worth ₹110 Cr

Indoco Remedies approved the slump sale of its Ophthalmic Division to Sunways (India) Private Limited for ₹110 Crore. The transaction covers territories including India and several African nations. The deal, representing 3.2% of Indoco's standalone revenue, is expected to conclude within three months as the company focuses on core therapeutic areas.

Value

₹110.0 Cr

Execution

About 3 months

Board Meeting Date

Indoco Remedies Board Meeting Date

Indoco Remedies Ltd has scheduled a Board Meeting on May 07, 2026. The board will consider and approve audited financial results for the quarter and year ended March 31, 2026, and recommend a final dividend for the fiscal year. The trading window remains closed until May 09, 2026.

Regulatory ApprovalAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Indoco Remedies Regulatory Approval

Indoco Remedies Limited announced that the U.S. FDA successfully completed a Pre-Approval Inspection at its testing facility in Chhatrapati Sambaji Nagar (Aurangabad). The inspection, conducted from April 08-10, 2026, concluded with zero Form 483 observations, confirming compliance with regulatory standards.